I am a computational biochemistry researcher specializing in structure-based drug design and molecular modeling to identify novel small-molecule inhibitors targeting cancer-related pathways. My academic interests focus on receptor tyrosine kinases (RTKs), angiogenesis, hypoxia, and metabolic reprogramming, with an emphasis on overcoming cancer resistance. I apply molecular docking, molecular dynamics simulations, DFT, QSAR, and ADMET analysis to design and evaluate multitarget compounds with potential therapeutic relevance.